<?xml version="1.0" encoding="UTF-8"?>
<ref id="B51-marinedrugs-17-00567">
 <label>51.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Petrova</surname>
    <given-names>M.I.</given-names>
   </name>
   <name>
    <surname>van den Broek</surname>
    <given-names>M.F.L.</given-names>
   </name>
   <name>
    <surname>Spacova</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Verhoeven</surname>
    <given-names>T.L.A.</given-names>
   </name>
   <name>
    <surname>Balzarini</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Vanderleyden</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Schols</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Lebeer</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Engineering lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin</article-title>
  <source>Int. J. Antimicrob. Agents</source>
  <year>2018</year>
  <volume>52</volume>
  <fpage>599</fpage>
  <lpage>607</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.07.013</pub-id>
  <?supplied-pmid 30040991?>
  <pub-id pub-id-type="pmid">30040991</pub-id>
 </element-citation>
</ref>
